

SPRINGER BRIEFS IN APPLIED SCIENCES AND  
TECHNOLOGY · FORENSIC AND MEDICAL BIOINFORMATICS

Amit Kumar · Ajit Kumar Saxena ·  
Gwo Giun (Chris) Lee · Amita Kashyap ·  
G. Jyothsna

Novel  
Coronavirus  
2019  
In-silico Vaccine  
Design and Drug  
Discovery

 Springer

# **SpringerBriefs in Applied Sciences and Technology**

Forensic and Medical Bioinformatics

## **Series Editors**

Amit Kumar, BioAxis DNA Research Centre Private Ltd, Hyderabad,  
Telangana, India

Allam Appa Rao, Hyderabad, India

More information about this subseries at <http://www.springer.com/series/11910>

Amit Kumar · Ajit Kumar Saxena ·  
Gwo Giun (Chris) Lee ·  
Amita Kashyap · G. Jyothsna

# Novel Coronavirus 2019

In-silico Vaccine Design and Drug Discovery

 Springer

Amit Kumar  
BioAxis DNA Research Centre Private Ltd  
Hyderabad, Telangana, India

Ajit Kumar Saxena  
All India Institute of Medical Sciences  
Patna, Bihar, India

Gwo Giun (Chris) Lee  
National Cheng Kung University  
Tainan, Taiwan

Amita Kashyap  
BioAxis DNA Research Centre Private Ltd  
Hyderabad, Telangana, India

G. Jyothsna  
BioAxis DNA Research Centre Private Ltd  
Hyderabad, Telangana, India

ISSN 2191-530X                      ISSN 2191-5318 (electronic)  
SpringerBriefs in Applied Sciences and Technology  
ISSN 2196-8845                      ISSN 2196-8853 (electronic)  
SpringerBriefs in Forensic and Medical Bioinformatics  
ISBN 978-981-15-7917-2            ISBN 978-981-15-7918-9 (eBook)  
<https://doi.org/10.1007/978-981-15-7918-9>

© The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd. 2020

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

# Preface

Hope you, your family and friends are safe. We are passing through quite a challenging time for society, and the crisis has left no one untouched. Coronavirus—COVID-19 is a common threat and declared pandemic by the World Health Organization. It is a call to action, responsibility and time to spread precautions and stop the fear going viral. The current situation affects everyone, and it demands all of us to play our part to contain this deadliest stigma to humanity. We mourn for the bereaved families and wish speedy recovery to the individuals and their families who are still suffering.

This book brings insights on current scenario of the COVID-19 along with drug and vaccine discovery approaches being worked out globally. Unfortunately, until we compile this book, there has not been any substantial success towards the cure of the COVID and whole scientific community is battling the intellectual war against this microorganism. Though MERS and nCoV-19 belong to the same family, there are visible differences in their etiology. There is a chapter on plasma therapy approach against COVID-19 which is widely experimented by several countries, but efficacy needs to be measured and studied based on the number of cases respond positive and get cured because of this technique.

Contents of the current book are useful to scientific fraternity and research students to gain whereabouts and knowledge related to in-silico vaccine and drug discovery against coronaviruses, statistics of COVID based on real-time datasets (Indian context specially), etiology of nCoV-19, therapies and tactics being workout against COVID-19 to control and check its deadliness and crisis caused because of its lethal spread.

We thank our Friends at BioAxis DNA Research Centre (P) Ltd., Hyderabad, Scientists in the Department of Pathology, All India Institute of Medical Sciences, Patna, for working hard and very meticulously to bring the current research work to a presentable stage in a quick timeline. This book is dedicated to all medical doctors, police personals, laboratory professionals and other corona warriors working day and night to save the humanity against this microorganism which we cannot see through our naked eyes. A big thank and salute to you all.

Please take a very good care of yourself, your families and friends, stay home and keep following the Government regulations. Let us make the world more resilient together.

Hyderabad, India  
Patna, India  
Tainan, Taiwan  
Hyderabad, India  
Hyderabad, India

Amit Kumar  
Ajit Kumar Saxena  
Gwo Giun (Chris) Lee  
Amita Kashyap  
G. Jyothsna

# Contents

<b>1</b>	<b>Insights of NCoV 19 and COVID19</b> .....	1
1.1	Symptoms and Characteristics of COVID19 .....	1
1.2	Statistics of COVID19 .....	2
1.3	SARS Corona Virus 2 .....	5
1.4	World Health Organization Response towards COVID19 .....	6
	References .....	7
<b>2</b>	<b>Genomics and Evolution of Novel Corona Virus 2019</b> .....	9
2.1	Important Regions Within the Novel Corona Virus Genome [2] .....	9
2.2	Linking NCoV with SARS and determining its genomic conservation .....	10
	References .....	12
<b>3</b>	<b>Comparing Proteomics of NCoV 19 and MERS Corona Virus</b> .....	13
3.1	ORF1ab Protein Sequence comparison of NCoV and MERS CoV .....	14
3.2	Comparison of Spike (S) Proteins of NCoV and MERS CoV .....	18
3.3	Comparison of Membrane (M) Proteins of NCoV and MERS CoV .....	19
3.4	Comparison of Envelope (E) Proteins of NCoV and MERS CoV .....	20
3.5	Comparison of Nucleocapsid (N) Proteins of NCoV and MERS CoV .....	21
3.6	Conclusion .....	22
	References .....	22
<b>4</b>	<b>Physiochemical Characterization and Domain Annotation of ORF1ab Polyprotein of Novel Corona Virus 19</b> .....	23
4.1	Physiochemical Characterization of ORF1ab Polyprotein Using Protparam .....	23



4.2	Identification of Domains within the ORF1ab Polyprotein using SMART . . . . .	24
4.3	The region 4406–5900 of ORF1ab polyprotein of NCoV . . . . .	30
4.4	The Secondary Structural Conformations of the Region 4406–5900 . . . . .	31
4.5	3D Structure prediction using Phyre . . . . .	31
4.6	3D Structure Visualization of the SARS Corona Virus 2 RNA-Dependent RNA Polymerase Protein in RASMOL . . . . .	33
4.7	Prediction of Disordered Sites Within the Protein Structure Based on GLOBPLOT . . . . .	34
	References . . . . .	35
<b>5</b>	<b>Rational Drug Design and Docking of the RNA Dependent RNA Polymerase Domain of NCoV . . . . .</b>	<b>37</b>
5.1	Selection Criteria for Chemicals . . . . .	38
5.2	Docking of the Chemicals in HEX . . . . .	39
5.3	Docking Results Summarized . . . . .	40
	References . . . . .	45
<b>6</b>	<b>Herbal Treatment Approach Towards COVID19 . . . . .</b>	<b>47</b>
6.1	Some of the Medicinal Plants in the COVID Therapy . . . . .	47
6.2	Zingiber Officinale/Ginger . . . . .	47
6.3	Allium Sativum/Garlic . . . . .	49
6.4	Tinospora Cordifolia/Giloy . . . . .	49
6.5	Ocimum Tenuiflorum/Tulsi and Withania Somnifera/Ashwaganda . . . . .	50
	References . . . . .	51
<b>7</b>	<b>Evolutionary and Structural Studies of NCoV and SARS CoV-Spike proteins and their association with ACE2 Receptor . . . . .</b>	<b>53</b>
7.1	Introduction . . . . .	53
7.2	Materials and Methods . . . . .	55
7.2.1	Collection of Sequences . . . . .	55
7.2.2	Phylogenetic Analysis . . . . .	55
7.2.3	Protein Structure Homology Modeling by ITASSER . . . . .	55
7.2.4	Protein-Protein Docking . . . . .	55
7.2.5	Structural and Functional Analysis of NCoV 19 and SARS-CoV Using Human ACE2 . . . . .	56
7.3	Results . . . . .	56
7.4	Discussion . . . . .	59
7.5	Conclusion . . . . .	60
	References . . . . .	60